Similar findings were observed in other three independent cohorts: a LUAD cohort treated with anti-PD1/PD-L1 (n = 28) (Figure 7E, Figure S7G) [54], a GBM cohort treated with anti-PD1 (n = 34) (Figure 7E) [55], and a KIRC cohort treated with anti-PD1 (n = 311) (Figure 7E) [56]. The gene discussed is CD274; the disease is glioblastoma.